Last reviewed · How we verify
NCT06024694
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
trial in Primary Mediastinal Large B-cell Lymphoma (PMBCL) in 45 participants. Participants enrolled and being followed up; not accepting new ones.
10 June 2026
Quick facts
| Lead sponsor | IRCCS San Raffaele |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 45 |
| Start date | 30 June 2022 |
| Primary completion | 10 June 2026 |
| Estimated completion | 10 June 2027 |
| Sites | 1 location across Italy |
Conditions studied
- Primary Mediastinal Large B-cell Lymphoma (PMBCL) — all drugs for Primary Mediastinal Large B-cell Lymphoma (PMBCL) →
Sponsor
IRCCS San Raffaele — full company profile →
Who can join
Adults 18 to 80, any sex, with Primary Mediastinal Large B-cell Lymphoma (PMBCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a retrospective, multicenter study focused on patients with a known diagnosis of PMLBCL which experienced a CNS relapse during the course of their disease to obtain information about the clinical characteristics, the management at diagnosis and at each relapses , and the outcome of these cases. The aim of the study is to put together the large International series on CNS+ PMLBCL data, coming from 6 different countries , on clinical factors, anti-lymphoma therapy administered alone or concomitant with CNS prophylaxis , the information about the site of re biopsy when available , the dose intensity of lymphoma therapy received at relapse and the outcome of patients. Both patients treated in routine practice or within clinical trials will be considered. Moreover to better characterized the pathological features of this rare entity a central pathological review of the initial diagnosis and when available of for histological confirmed relapse will be considered.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06024694
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Currently open trials in the same condition.
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
- NCT06486051 — A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma · Phase 2 · recruiting
- NCT05934084 — Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors · NA · recruiting
- NCT05934448 — Pembro Plus CAR T-cell Therapy in R/R in PMBCL · Phase 2 · recruiting
- NCT06026319 — CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma · Phase 1 · recruiting
Other IRCCS San Raffaele trials
Trials by the same sponsor.
- NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
- NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
- NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
- NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
- NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06024694 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06024694.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing